Company profile: Protomer
1.1 - Company Overview
Company description
- Provider of pre-clinical biotechnology R&D focused on metabolic diseases, developing glucose-responsive insulin receptor agonist therapeutics and the Molecular Evolution of Peptide Sensors (MEPS) platform for creating therapeutic peptides and proteins with tunable, small-molecule-controlled activity.
Products and services
- Metabolic Disease Research and Technology Development: Pre-clinical-stage biotechnology program focused on metabolic diseases develops therapeutic peptides and proteins with tunable activity controlled by small molecules to progress candidate biologics
- Molecular Evolution of Peptide Sensors (MEPS) Platform: Chemical biology-based platform architects therapeutic peptides and proteins with tunable activity controlled by small molecules, enabling ligand-responsive peptide sensors for metabolic disease therapeutics
- Glucose-Responsive Insulin Receptor Agonists: Glucose-responsive therapeutic candidates modulate insulin receptor activity based on blood glucose levels to precisely align activation with metabolic state
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Protomer
Poxel
HQ: France
Website
- Description: Provider of biopharmaceutical products for metabolic diseases, focusing on type 2 diabetes and NASH. Portfolio includes TWYMEEG (Imeglimin), approved in Japan for type 2 diabetes, targeting mitochondrial dysfunction; PXL065, a deuterium-stabilized R-pioglitazone for NASH with Phase 2 primary endpoint met; and PXL770, a direct AMPK activator for rare diseases including NASH and ALD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Poxel company profile →
Jana Care
HQ: United States
Website
- Description: Provider of smartphone-based diagnostics and connected blood testing, using the Aina optical reader to turn smartphones into diagnostic platforms that analyze paper-based test strips across multiple assays; transmits results to physicians to enable telehealth and chronic disease monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jana Care company profile →
Lifecare
HQ: Norway
Website
- Description: Provider of miniaturized, implantable glucose sensors and nano biosensing solutions. Offerings include Sencell, a real-time glucose sensor measuring osmotic pressure, lasting at least six months and transmitting data wirelessly to smart devices; NanoBioSensors for high-resolution diagnostics in live tissue; and Lifecare Veterinary for continuous animal glucose monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lifecare company profile →
Modulim
HQ: United States
Website
- Description: Provider of light-based imaging and care management solutions: Clarifi Imaging System, a non-contact, noninvasive tool using spatial frequency domain imaging to assess microvascular health by measuring tissue oxygenation and perfusion; LAMP, integrating patient assessment, data management, and care coordination; Modulim Cloud, a HIPAA-compliant platform for secure data and imaging; and Magnifi Software for tailored views and remote care collaboration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modulim company profile →
SmartCells
HQ: United States
Website
- Description: Provider of insulin and polymer-based products for diabetes, including SmartInsulin, a self-regulating injectable formulation, and polymer-based dosing technology for applications in fertility, thyroid, and growth hormone deficiencies, and treatments with poor compliance or therapeutic window.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartCells company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Protomer
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Protomer
2.2 - Growth funds investing in similar companies to Protomer
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Protomer
4.2 - Public trading comparable groups for Protomer
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →